CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 253.35 AUD -0.77%
Market Cap: 122.7B AUD

Relative Value

The Relative Value of one CSL stock under the Base Case scenario is 272.79 AUD. Compared to the current market price of 253.35 AUD, CSL Ltd is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CSL Relative Value
Base Case
272.79 AUD
Undervaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
54
Median 3Y
6.7
Median 5Y
8.4
Industry
7.3
Forward
4.9
vs History
98
vs Industry
4
Median 3Y
38.2
Median 5Y
39.2
Industry
21.6
Forward
24.5
vs History
87
vs Industry
5
Median 3Y
33.5
Median 5Y
33.5
Industry
19.8
vs History
60
vs Industry
1
Median 3Y
55.3
Median 5Y
71.1
Industry
24.9
vs History
98
vs Industry
15
Median 3Y
5.6
Median 5Y
6.4
Industry
2.4
vs History
98
vs Industry
44
Median 3Y
7.3
Median 5Y
8.8
Industry
7.4
Forward
5.4
vs History
98
vs Industry
29
Median 3Y
14.2
Median 5Y
16.1
Industry
9.3
vs History
98
vs Industry
5
Median 3Y
22.9
Median 5Y
25
Industry
3.9
Forward
15.8
vs History
98
vs Industry
4
Median 3Y
28.5
Median 5Y
29.8
Industry
3.7
Forward
18.9
vs History
80
vs Industry
4
Median 3Y
35.8
Median 5Y
35.8
Industry
4.9
vs History
88
vs Industry
2
Median 3Y
81.9
Median 5Y
80.5
Industry
3.2
vs History
98
vs Industry
39
Median 3Y
3.2
Median 5Y
5.6
Industry
4.3

Multiples Across Competitors

CSL Competitors Multiples
CSL Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
CSL Ltd
ASX:CSL
123.6B AUD 5.1 28.3 17.4 21.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 547 712.8 -173 705.9 -210 934.3 -208 527.2
US
Abbvie Inc
NYSE:ABBV
374.2B USD 6.6 88.3 17.2 26
US
Amgen Inc
NASDAQ:AMGN
169.1B USD 5.1 41.4 16.6 29.4
US
Gilead Sciences Inc
NASDAQ:GILD
131.5B USD 4.6 273.9 10.8 13.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.9B USD 11.9 -244.5 26.8 28.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 927.6 -491.9 -535.6 -521.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.6B USD 5.1 16.5 10.8 12.1
US
Seagen Inc
F:SGT
39.3B EUR 18.6 -56.9 -61.3 -55.3
NL
argenx SE
XBRU:ARGX
34B EUR 16.8 44.3 327.8 -2 414.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
32.8B USD 14.6 -117.9 -258.8 -175.9
P/S Multiple
Revenue Growth P/S to Growth
AU
CSL Ltd
ASX:CSL
Average P/S: 3 322 702.6
5.1
7%
0.7
FR
Pharnext SCA
OTC:PNEXF
36 547 712.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.9
10%
1.2
US
E
Epizyme Inc
F:EPE
1 927.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
7%
0.7
US
S
Seagen Inc
F:SGT
18.6
30%
0.6
NL
argenx SE
XBRU:ARGX
16.8
37%
0.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.6
28%
0.5
P/E Multiple
Earnings Growth PEG
AU
CSL Ltd
ASX:CSL
Average P/E: 82.1
28.3
16%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 705.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.3
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.4
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
273.9
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -244.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -491.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A N/A
NL
argenx SE
XBRU:ARGX
44.3
19%
2.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -117.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBITDA: 61.1
17.4
12%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 934.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.6
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.8
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.3 N/A N/A
NL
argenx SE
XBRU:ARGX
327.8
168%
2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -258.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBIT: 21.8
21.8
14%
1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 527.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.4
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.5
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 414.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -175.9 N/A N/A